Citadel Advisors’s Audentes Therapeutics BOLD Stock Holding History
Bought
Maintained
Sold
Citadel Advisors's BOLD Position: Q4 2019 in Review
Citadel Advisors sold out of Audentes Therapeutics (BOLD) in Q4 2019, closing a stake of 1,017,783 shares — an estimated $38.2M sold.
Citadel Advisors first reported a position in BOLD in Q1 2017 and held it in 10 quarters. The position peaked at $28.6M in Q3 2019. 188 funds tracked by Wall St. Rank hold BOLD as of Q4 2019.
- Citadel Advisors reported no remaining Audentes Therapeutics position as of Q4 2019 after selling out during the quarter.
- Citadel Advisors sold 1,017,783 Audentes Therapeutics shares in Q4 2019, an estimated $38.2M.
- Citadel Advisors first reported a position in Audentes Therapeutics in Q1 2017 and held it in 10 quarters.
- Citadel Advisors's Audentes Therapeutics position peaked at $28.6M in Q3 2019.
- 188 funds tracked by Wall St. Rank held Audentes Therapeutics as of Q4 2019.
Based on Citadel Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.